Conoscere EBM
- Definizione
- Acronimi
- Cronologia
- Ambiti
- Know-how e strumenti
- EBM in 4 step
- Limiti e ostacoli

EB Practice
- Formulazione quesito
- Ricerca evidenze
- Valutazione evidenze
- Applicazione evidenze

EBHC Library
- Risorse in italiano

SSN Hot Topics
- Appropriatezza
- Conflitti di interesse
- ECM
- Farmaci
- Governo Clinico
- LEA

InfoSanità

Archivio > News 2010

Page last update: 24/01/2012

• BMJ, 1 gennaio

  • Industry sponsored bias in cost effectiveness analyses

   

• N Engl J Med, 23 dicembre

  • What Is Value in Health Care?

  • Variability in the Measurement of Hospital-wide Mortality Rates

• JAMA 22/29 dicembre

  • A Behavioral and Systems View of Professionalism

• BMJ, 18 dicembre

  • Self experimentation and the Nuremberg Code

  • Strategies for coping with information overload

  • On the impossibility of being expert

• CMAJ, 14 dicembre

  • AGREE II: advancing guideline development, reporting and evaluation in health care

• Ann Intern Med, 7 dicembre

  • Competency-Based Education and Training in Internal Medicine

• BMJ, 4 dicembre

  • Referral from primary to secondary care

  • Explaining variation in referral from primary to secondary care: cohort study

• Lancet, 4 dicembre

  • A new epoch for health professionals' education

  • Health professionals for the 21st century: a students' view

  • Health professionals for a new century: transforming education to strengthen health systems in an interdependent world

• N Engl J Med, 2 dicembre

  • Shattuck Lecture: Innovation, Regulation, and the FDA

• JAMA, 1 dicembre

  • Toward an Outcomes-Based Health Care System: A View From the United Kingdom

• BMJ, 27 novembre

  • Three techniques for integrating data in mixed methods studies

• N Engl J Med, 25 novembre

  • Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone

  • Pharmaceutical Marketing and the New Social Media

• JAMA,  24 novembre

  • How to Use an Article About Quality Improvement

  • The Evolution of Population Science: Advent of the Mega Cohort

  • Enhancing the Feasibility of Large Cohort Studies

  • Academic Medical Centers' Conflict of Interest Policies

• BMJ, 20 novembre

  • The problem of orphan drugs

  • What makes an orphan drug?

  • Orphan drug pricing may warrant a competition law investigation

  • Is open peer review the fairest system? Yes

  • Is open peer review the fairest system? No

• PLoS Med, 16 novembre

  • Defining Research to Improve Health Systems

• Ann Intern Med, 16 novembre

  • Streamlining Ethical Review

• BMJ, 13 novembre

  • After the abolition of the National Patient Safety Agency

  • The future role of NICE

  • NICE and value based pricing: what do we know?

  • Drug pricing, NICE, and the PPRS: government gets it right

  • Health technology assessments: what do differing conclusions tell us?

  • Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review

  • Quality Improvement Report. Effect of a “Lean” intervention to improve safety processes and outcomes on a surgical emergency unit

• N Engl J Med, 11 novembre

  • Effect of a Comprehensive Surgical Safety System on Patient Outcomes

  • Strategies for Improving Surgical Quality — Checklists and Beyond

• JAMA, 10 novembre

  • The Rational Clinical Examination. Does This Patient Have Malaria?

  • Desktop Medicine

• PLoS Med, 9 novembre

  • Strategies for Increasing Recruitment to Randomised Controlled Trials: Systematic Review

• CMAJ, 9 novembre

  • Substituting placebo for established, effective therapy: Why not?

• BMJ, 6 novembre

  • Regulation of devices

• Lancet. 6 novembre

  • Drug harms in the UK: a multicriteria decision analysis

• N Engl J Med, 4 novembre

  • Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation

• PLoS Med, 2 novembre

  • Doctors and Drug Companies: Still Cozy after All These Years

  • Why Do Evaluations of eHealth Programs Fail? An Alternative Set of Guiding Principles

• Ann Intern Med, 2 novembre

  • Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership

• Lancet, 30 ottobre

  • Does instant access to compiled information undermine clinical cognition?

• JAMA, 27 ottobre

  • The End of the Quality Improvement Movement: Long Live Improving Value

• PLoS Med, 26 ottobre

  • Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study

  • Editors, Publishers, Impact Factors, and Reprint Income

  • Increased Responsibility and Transparency in an Era of Increased Visibility

• BMJ, 23 ottobre

  • Assessing equity in systematic reviews: realising the recommendations of the Commission on Social Determinants of Health

• N Engl J Med, 21 ottobre

  • Public Release of Clinical Outcomes Data — Online CABG Report Cards

• JAMA, 20 ottobre

  • Meaningful Use of Electronic Health Records: The Road Ahead

  • Putting the Public Back in Public Reporting of Health Care Quality

  • Making Research Consent Transparent

  • Accountable Care Organizations: Accountable for What, to Whom, and How

  • Improving Teamwork to Reduce Surgical Mortality

• Ann Intern Med, 19 ottobre

  • What's in Placebos: Who Knows? Analysis of Randomized, Controlled Trials

  • Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review

• CMAJ, 19 ottobre

  • Registration of observational studies: Is it time?

• BMJ, 15 ottobre

  • Missing clinical trial data: setting the record straight

  • Misleading communication of risk

  • Finding studies on reboxetine: a tale of hide and seek

  • Select this articleData availability for industry sponsored trials: what should medical journals require?

  • Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

• N Engl J Med, 14 ottobre

  • Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration

  • Reviving the FDA

  • Legislating against Use of Cost-Effectiveness Information

• JAMA, 13 ottobre

  • Managing Medications in Clinically Complex Elders: "There's Got to Be a Happy Medium"

  • Medication Use in Older Patients: Better Policy Could Encourage Better Practice

• PLoS Med, 12 ottobre

  • Being More Realistic about the Public Health Impact of Genomic Medicine

• Lancet, 9 ottobre

  • FDA: regulators or abdicators?

  • Measuring and improving health-system productivity

  • Use of mass media campaigns to change health behaviour

• BMJ, 9 ottobre

  • The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence

• JAMA, 6 ottobre

  • Evaluating the Risks of Clinical Research

  • What If Physicians Actually Had to Control Medical Costs?

  • What Physician-Investigators Owe Patients Who Participate in Research

  • Implementation of the ICMJE Form for Reporting Potential Conflicts of Interest

• PLoS Med, 5 ottobre

  • A Field Training Guide for Human Subjects Research Ethics

• Ann Intern Med, 5 ottobre

  • Comparative Effectiveness Research: A Progress Report

• CMAJ, 5 ottobre

  • A framework for research ethics review during public emergencies

• BMJ, 2 ottobre

  • Continuing medical education across Europe

  • Merging of marketing and medical science: female sexual dysfunction

  • Maintaining the competence of Europe’s workforce

  • Impact of workplace based assessment on doctors’ education and performance: a systematic review

  • Evaluating policy and service interventions: framework to guide selection and interpretation of study end points

• Lancet, 2 ottobre

  • Singapore Statement: a global agreement on responsible research conduct

  • AGREE II—improving the quality of clinical care

• N Engl J Med, 30 settembre

  • Placebo-Controlled Trials in Osteoporosis — Proceeding with Caution

  • The Ethics of Placebo in Studies with Fracture End Points in Osteoporosis

• Arch Intern Med, 27 settembre

  • Incidental Findings in Imaging Research: Evaluating Incidence, Benefit, and Burden

  • Responding to Incidental Findings on Research Imaging Studies: Now What?

• BMJ, 25 settembre

  • Is it time to revisit orphan drug policies?

  • Streamlined research governance: are we there yet?

• Lancet, 25 settembre

  • Innovation or regulation: IDEAL opportunity for consensus

  • Ethical challenges of innovative surgery: a response to the IDEAL recommendations

• PLoS Med, 21 settembre

  • Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?

• Ann Intern Med, 21 settembre

  • Select this articleClinical Trials: Discerning Hype From Substance

• JAMA, 15 settembre

  • Theme Issue: Medical Education

• Arch Intern Med, 13 settembre

  • Ambulatory Patient Safety: The Time Is Now

• BMJ, 11 settembre

  • Licensing drugs for diabetes

  • FDA guidance on patient reported outcomes

  • Drug Regulation: Rosiglitazone: what went wrong?

  • Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?

• Lancet, 11 settembre

  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases

• N Engl J Med, 9 settembre

  • Patient Safety beyond the Hospital

• PLoS, 7 settembre

  • The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

• CMAJ, 7 settembre

  • Competing interests and undergraduate medical education: time for transparency

• Ann Intern Med, 7 settembre

  • The Effect of Financial Incentives on Hospitals That Serve Poor Patients

  • Does Pay-for-Performance Steal From the Poor and Give to the Rich?

  • Improving the Quality of Informed Consent: It Is Not All About the Risks

• N Engl J Med, 2 settembre

  • The Disclosure Dilemma — Large-Scale Adverse Events

• JAMA, 1 settembre

  • A New Research and Development Policy Framework for the Biomedical Research Enterprise

  • Improving Access to Health Care Data

• PLoS Med, 30 agosto

  • Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders

• BMJ, 28 agosto

  • Importance of accurately identifying chronic disease in studies using electronic health records

• Lancet, 28 agosto

  • The James Lind Alliance: tackling research mismatches

• N Engl J Med, 26 agosto

  • Revisiting the Rosiglitazone Story — Lessons Learned

• JAMA, 25 agosto

  • The Rational Clinical Examination. Does This Coughing Adolescent or Adult Patient Have Pertussis?

  • Minimizing Bias Due to Confounding by Indication in Comparative Effectiveness Research: The Importance of Restriction

  • Comparative Effectiveness—of What?: Evaluating Strategies to Improve Population Health

• BMJ, 21 agosto

  • Interpreting composite outcomes in trials

  • Inadequate post-publication review of medical research

  • Open access publication fees at the BMJ

  • Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study

  • Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review

  • Adequacy of authors’ replies to criticism raised in electronic letters to the editor: cohort study

  • Taking healthcare interventions from trial to practice

• N Engl J Med, 19 agosto

  • New Technology and Health Care Costs — The Case of Robot-Assisted Surgery

  • New Priorities for Future Biomedical Innovations

• JAMA, 18 agosto

  • The Rational Clinical Examination. Does This Patient Have Delirium? Value of Bedside Instruments

  • The US Global Health Initiative: Informing Policy With Evidence

  • Minimizing Bias in Randomized Trials: The Importance of Blinding

  • Physician Compensation, Cost, and Quality

• PLoS Med, 17 agosto

  • The Costs and Underappreciated Consequences of Research Misconduct: A Case Study

• N Engl J Med, 12 agosto

  • Disclosing Industry Relationships — Toward an Improved Federal Research Policy

  • Quality Measures and the Individual Physician

  • Accountability Measures — Using Measurement to Promote Quality Improvement

• JAMA, 11 agosto

  • Evaluation of Comparative Treatment Trials: Assessing Clinical Benefits and Risks for Patients, Rather Than Statistical Effects on Measures

  • Should Sensitive Information From Clinical Trials Be Included in Electronic Medical Records?

• N Engl J Med, 5 agosto

  • The “Meaningful Use” Regulation for Electronic Health Records

  • Finding My Way to Electronic Health Records

• Ann Intern Med, 3 agosto

  • Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

  • The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of Methods

  • Toward More Uniform Conflict Disclosures: The Updated ICMJE Conflict of Interest Reporting Form

• BMJ, 31 luglio

  • Improving productivity in the NHS

  • Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study

• Lancet, 31 luglio

  • Vienna Declaration: a call for evidence-based drug policies

• BMJ, 24 luglio

  • Reorganisation of the NHS in England

  • Quality Improvement Report. Reducing Clostridium difficile infection in acute care by using an improvement collaborative

• N Engl J Med, 22 luglio

  • Cancer Clinical Trials — A Chronic but Curable Crisis

• Ann Intern Med, 20 luglio

  • Plagiarism in Residency Application Essays

  • Plagiarism on Personal Statements: A Disturbing Symptom of a Broader Trend

  • Open Notes: Doctors and Patients Signing On

• JAMA, 14 luglio

  • Physicians' Perceptions, Preparedness for Reporting, and Experiences Related to Impaired and Incompetent Colleagues

  • Checklists and Guidelines: Imaging Techniques for Visualizing What to Do

• CMAJ, 13 luglio

  • Toward more uniform conflict disclosures: updated ICMJE conflict of interest reporting form

  • Are we keeping research participants safe enough?

  • Development of the AGREE II, part 2: assessment of validity of items and tools to support application

  • Development of the AGREE II, part 1: performance, usefulness and areas for improvement

• N Engl J Med, 8 luglio

  • Identifying and Eliminating the Roadblocks to Comparative-Effectiveness Research

  • Toward More Uniform Conflict Disclosures — The Updated ICMJE Conflict of Interest Reporting Form

• JAMA, 7 luglio

  • The Rational Clinical Examination. Can This Patient Read and Understand Written Health Information?

  • Meaningful Use of Health Information Technology Is Managing Information

  • Procedure Volume as a Predictor of Surgical Outcomes

• Ann Intern Med, 6 luglio

  • Aggregating and Disaggregating Patients in Clinical Trials and Their Subgroup Analyses

• Lancet, 3 luglio

  • Putting research into context—revisited

  • Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting

• BMJ, 3 luglio

  • Towards more uniform conflict disclosures

  • What attributes should clinical ethics committees have?

  • Modified intention to treat reporting in randomised controlled trials: systematic review

• Arch Intern Med, 28 giugno

  • When Clinical Practice Guidelines Meet the Black Box

  • Patient Record Review of the Incidence, Consequences, and Causes of Diagnostic Adverse Events

  • Diagnostic Adverse Events: On to Chapter 2: Comment on "Patient Record Review of the Incidence, Consequences, and Causes of Diagnostic Adverse Events"

• BMJ, 26 giugno

  • Do summary care records have the potential to do more harm than good? YES

  • Do summary care records have the potential to do more harm than good? NO

  • Random measurement error and regression dilution bias

• N Engl J Med, 24 giugno

  • Transparency at the Food and Drug Administration

• JAMA, 23/30 giugno

  • Adherence to Surgical Care Improvement Project Measures and the Association With Postoperative Infections

  • Surgical Care Improvement: Should Performance Measures Have Performance Measures

• BMJ, 19 giugno

  • Should the Quality and Outcomes Framework be abolished? Yes

  • Should the Quality and Outcomes Framework be abolished?  No

  • Controversy over generic substitution

• JAMA, 16 giugno

  • Managing Financial Conflict of Interest in Biomedical Research

  • Quality of Care—How Good Is Good Enough?

  • Payment Policy Based on Measurement of Health Care Spending and Outcomes

• JAMA, 9 giugno

  • The Rational Clinical Examination. Does This Patient Have a Hemorrhagic Stroke?

• PLoS, 8 giugno

  • Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT Statement

• BMJ, 5 giugno

  • How New Zealand has contained expenditure on drugs

• JAMA, 2 giugno

  • Using Science to Improve the Nation's Health System: NIH's Commitment to Comparative Effectiveness Research

• Ann Intern Med, 1 giugno

  • CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

  • The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution

• BMJ, 29 maggio

  • Need for a wider view of autonomy in epidemiological research

  • An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials

• JAMA, 26 maggio

  • Reporting and Interpretation of Randomized Controlled Trials With Statistically Nonsignificant Results for Primary Outcomes

  • Managing Financial Conflict of Interest in Biomedical Research

• Arch Intern Med, 24 maggio

  • Transforming Trial Results Into Practice Change

• Lancet, 22 maggio

  • European Medicines Agency—more transparency needed

• Ann Intern Med, 18 maggio

  • The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution

• BMJ, 15 maggio

  • Community pharmacy: moving from dispensing to diagnosis and treatment

  • The impact of removing financial incentives from clinical quality indicators: longitudinal analysis of four Kaiser Permanente indicators

• JAMA, 12 maggio

  • Health Care Is Different—That's Why Expenditures Matter

• Arch Intern Med, 10 maggio

  • Less Is More: How Less Health Care Can Result in Better Health

• CMAJ, 10 maggio

  • Competing interests and undergraduate medical education: time for transparency

• N Engl J Med, 6 maggio

  • Effect of Bar-Code Technology on the Safety of Medication Administration

• BMJ, 1 maggio

  • How can we make audit sexy?

  • Assessing the quality of hospitals

  • Has the European Clinical Trials Directive been a success?

  • Using hospital mortality rates to judge hospital performance: a bad idea that just won’t go away

  • Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design

• N Engl J Med, 29 aprile

  • Engaging Specialists in Performance-Incentive Programs

• JAMA, 28 aprile

  • What Makes a Good Predictor?: The Evidence Applied to Coronary Artery Calcium Score

• PLoS, 27 aprile

  • Comparative Effectiveness Research: Challenges for Medical Journals

• Arch Intern Med, 26 aprile

  • Public Disclosure of Conflicts of Interest: Moving the Policy Debate Forward

  • The Impact of Disclosing Financial Ties in Research and Clinical Care: A Systematic Review

  • Comparative Analysis of Different Approaches to Report Diagnostic Accuracy

• BMJ, 24 aprile

  • How to identify when a performance indicator has run its course

• JAMA 21 aprile

  • The Rational Clinical Examination. Does This Patient With Diabetes Have Large-Fiber Peripheral Neuropathy?

• BMJ, 17 aprile

  • Improving pharmacovigilance in Europe

  • Can the NHS cut costs without substantially damaging the quality of health care

  • Europe’s opportunity to open up drug regulation

  • Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses

  • Quality Improvement Report: Using care bundles to reduce in-hospital mortality: quantitative survey

• Lancet 17 aprile

  • A collapse in integrity of scientific advice in the UK

• Arch Intern Med, 12 aprile

  • Cautionary Tales in the Interpretation of Clinical Studies Involving Older Persons

  • Comparative Effectiveness Research: Critically Intertwined With Health Care Reform and the Future of Biomedical Innovation

• BMJ, 10 aprile

  • Rosiglitazone, marketing, and medical science

  • Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review

• Lancet, 10 aprile

  • Strengthening the credibility of clinical research

• JAMA, 7 aprile

  • The Rational Clinical Examination. Will This Patient Develop Persistent Disabling Low Back Pain?

• CMAJ, 6 aprile

  • Strategies to decrease the rate of preventable readmission to hospital

  • Good prescribing: better systems and prescribers needed

  • Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community

• BMJ, 3 apriile

  • Problems with peer review

• Lancet, 3 aprile

  • CONSORT 2010

  • Improving quality of care in the NHS

  • Education of health professionals for the 21st century: a global independent Commission

  • CONSORT 2010 changes and testing blindness in RCTs

• N Engl J Med, 1 aprile

  • Modernizing Device Regulation

  • Improving the Security and Privacy of Implantable Medical Devices

• JAMA 24/31 marzo

  • Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects: Systematic Review and Meta-regression Analysis

  • Psychiatrists' Relationships With Pharmaceutical Companies: Part of the Problem or Part of the Solution?

  • Ensuring Integrity in Industry-Sponsored Research: Primum Non Nocere, Revisited

  • Setting the RECORD Straight
     

• PLos, 24 marzo

  • CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials
     

• Ann Intern Med, 24 marzo

  • CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
     

• BMJ, 23 marzo

  • The new CONSORT statement

  • CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

  • The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed

  • The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews
     

• CMAJ, 23 marzo

  • Effect of point-of-care computer reminders on physician behaviour: a systematic review
     

• Arch Intern Med, 22 marzo

  • Cancer and the Media. How Does the News Report on Treatment and Outcomes?

  • Covering Cancer. Comment on "Cancer and the Media"

• N Engl J Med, 18 marzo 2010

  • Five Next Steps for a New National Program for Comparative-Effectiveness Research

• BMJ, 13 marzo

  • Graphic medicine: use of comics in medical education and patient care

  • Will a market deliver quality and efficiency in health care better than central planning ever could?

• Lancet, 13 marzo

  • The role of academic health science systems in the transformation of medicine

• JAMA, 10 marzo

  • Characteristics of Published Comparative Effectiveness Studies of Medications

  • Building Comparative Efficacy and Tolerability Into the FDA Approval Process

  • Charting a Path From Comparative Effectiveness Funding to Improved Patient-Centered Health Care

  • Promoting Science Education

• Arch Intern Med, 8 marzo

  • Patient-Centered Comparative Effectiveness Research: Essential for High-Quality Care

  • Statistical Numeracy for Health: A Cross-cultural Comparison With Probabilistic National Samples

  • Collective Statistical Illiteracy: A Cross-Cultural Comparison With Probabilistic National Samples: Comment on "Statistical Numeracy for Health"

• BMJ, 6 marzo

  • Meta-analysis of individual participant data: rationale, conduct, and reporting

• BMJ, 27 febbraio

  • Publishing information about ongoing clinical trials for patients

  • The routine use of patient reported outcome measures in healthcare settings

• N Engl J Med, 25 febbraio

  • Serving Two Masters — Conflicts of Interest in Academic Medicine

• JAMA, 24 febbraio

  • Registering Clinical Trial Results: The Next Step

• CMAJ, 23 febbraio

  • Measuring performance is essential to patient-centred care

• Arch Intern Med, 22 febbraio

  • Decreasing Hospital Costs While Maintaining Quality: Can It Be Done?

  • Pharmaceutical Industry Support and Residency Education: A Survey of Internal Medicine Program Directors

• Lancet, 20 febbraio

  • Biological, clinical, and ethical advances of placebo effects

• BMJ, 20 febbraio

  • The prognosis for research

  • Registration of observational studies

  • Has guideline development gone astray? Yes

  • Has guideline development gone astray? No

  • Ten steps towards improving prognosis research

• Ann Intern Med, 16 febbraio

  • Improving Patient Care. Frequency of Inappropriate Medical Exceptions to Quality Measures

• PLoS Med, 16 febbraio

  • Guidance for Developers of Health Research Reporting Guidelines

• Lancet, 13 febbraio

  • Evidence-based medicine in China

• BMJ, 13 febbraio

  • Higher hospital volume and specialisation

• CMAJ, 12 febbraio

  • Knowledge creation: synthesis, tools and products

  • The knowledge-to-action cycle: identifying the gaps

  • Adapting clinical practice guidelines to local context and assessing barriers to their use

  • Developing and selecting interventions for translating knowledge to action

  • Selecting educational interventions for knowledge translation

  • Monitoring use of knowledge and evaluating outcomes

• JAMA, 10 febbraio

  • Replicating High-Quality Medical Care Organizations

• Lancet, 6 febbraio

  • Fabricated or induced illness by carers: a complex conundrum

• BMJ, 6 febbraio

  • Will financial incentives and penalties improve hospital care?

  • Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewer

• N Engl J Med, 4 febbraio

  • Comparative Effectiveness and Health Care Spending — Implications for Reform

• JAMA, 3 febbraio

  • Safe Electronic Health Record Use Requires a Comprehensive Monitoring and Evaluation Framework

  • Electronic Health Records in the Age of Social Networks and Global Telecommunications

  • Evidence-Based Medicine Requires Appropriate Clinical Context

• PLoS, 2 febbraio

  • Ghostwriting at Elite Academic Medical Centers in the United States

• Lancet, 30 gennaio

  • The perils of journal and supplement publishing

  • Should protocols for observational research be registered?

  • A flexible blueprint for the future of drug development

  • Comparative effectiveness research stalls in the USA

  • A framework for mandatory impact evaluation to ensure well informed public policy decisions

• BMJ, 30 gennaio

  • NICE and new: appraising innovation

• JAMA, 27 gennaio

  • Continuing Medical Education: Let the Guessing Begin

• PLoS, 26 gennaio

  • Science Must Be Responsible to Society, Not to Politics

• Arch Intern Med, 25 gennaio

  • Drug Safety: Are We Making Progress?: Comment on "Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data"

• BMJ, 23 gennaio

  • Use of multiperspective qualitative interviews to understand patients’ and carers’ beliefs, experiences, and needs

• N Engl J Med, 21 gennaio

  • Accelerating the Use of Electronic Health Records in Physician Practices

• BMJ, 16 gennaio

  • Should healthy volunteers in clinical trials be paid according to risk? Yes

  • Should healthy volunteers in clinical trials be paid according to risk? No

• JAMA, 13 gennaio

  • Funding of US Biomedical Research, 2003-2008

  • Insights From Trends in Biomedical Research Funding

• CMAJ, 12 gennaio

  • Disseminate time-sensitive research faster

  • Registering systematic reviews

• Arch Intern Med, 11 gennaio

  • Systematic Review of Guidelines on Cardiovascular Risk Assessment: Which Recommendations Should Clinicians Follow for a Cardiovascular Health Check?

  • Screening for High-Risk Cardiovascular Disease: A Challenge for the Guidelines

• BMJ, 9 gennaio

  • Is primary care research a lost cause?

• Ann Intern Med, 5 gennaio

  • Spending More to Save More: Interventions to Promote Adherence

• PLoS, 5 gennaio

  • Are Patents Impeding Medical Care and Innovation?

• Lancet, 2 gennaio

  • The financial challenge facing the NHS

  • Drug development for neglected diseases: pharma's influence

• BMJ, 2 gennaio

  • Aubrey Blumsohn: Academic who took on industry

  • Bias in identifying and recruiting participants in cluster randomised trials: what can be done?

• N Engl J Med, 31 dicembre

  • Public Reporting of Discharge Planning and Rates of Readmissions